AR127653A1 - Derivados de ésteres de n⁴-hidroxicitidina y su uso - Google Patents
Derivados de ésteres de n⁴-hidroxicitidina y su usoInfo
- Publication number
- AR127653A1 AR127653A1 ARP220103112A ARP220103112A AR127653A1 AR 127653 A1 AR127653 A1 AR 127653A1 AR P220103112 A ARP220103112 A AR P220103112A AR P220103112 A ARP220103112 A AR P220103112A AR 127653 A1 AR127653 A1 AR 127653A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- membered
- cycloalkyl
- halo
- acyl
- Prior art date
Links
- XCUAIINAJCDIPM-XVFCMESISA-N N(4)-hydroxycytidine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=NO)C=C1 XCUAIINAJCDIPM-XVFCMESISA-N 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- -1 N4-hydroxycytidine ester Chemical class 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 2
- 125000006625 (C3-C8) cycloalkyloxy group Chemical group 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se refiere a derivados de éster de N⁴-hidroxicitidina (NHC), a composiciones farmacéuticas que los comprenden, al método de preparación de los mismos, y al uso y método de los derivados de éster de N⁴-hidroxicitidina para tratar infecciones virales. Reivindicación 1: Un compuesto de la fórmula (1) o un tautómero, estereoisómero o racemato del mismo o una sal farmacéuticamente aceptable del mismo, en donde R es Rᵃ-(C=O)-; en donde Rᵃ se selecciona del grupo que consiste en alquilo C₁₋₇, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈, arilo C₆₋₁₀, heteroarilo de 5 a 10 miembros, heterocicloalquilo de 3 a 12 miembros, cicloalquilo C₃₋₈-alquilo C₁₋₇, aril C₆₋₁₀-alquilo C₁₋₇, heteroaril-alquilo C₁₋₇ de 5 a 10 miembros y heterocicloalquil-alquilo C₁₋₇ de 3 a 12 miembros, en donde cada uno de dichos alquilo, cicloalquilo, arilo, heteroarilo y heterocicloalquilo está opcionalmente sustituido con uno o más sustituyentes seleccionados de los siguientes grupos: halógeno, acilo, hidroxi, ciano, nitro, amino, -NH(alquilo C₁₋₇), -N(alquilo C₁₋₇)₂, -CO-NH₂, -CO-NH(alquilo C₁₋₇), -CO-N(alquilo C₁₋₇)₂, -NH(acilo), -N(acilo)₂, NH₂-acilo, NHRʸ-acilo, N(Rʸ)₂-acilo, alquilo C₁₋₇, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxi C₁₋₇, ariloxi, heteroariloxi, halo-alquilo C₁₋₇, halo-alcoxi C₁₋₇, halo-alquenilo C₂₋₆, halo-alquinilo C₂₋₆, hidroxi-alquilo C₁₋₇, alcoxi C₁₋₇-alquilo C₁₋₇, halo-alcoxi C₁₋₇-alquilo C₁₋₇, halo-cicloalquilo C₃₋₈, cicloalquilo C₃₋₈, arilo C₆₋₁₀, heteroarilo de 5 a 10 miembros, heterocicloalquilo de 3 a 12 miembros, cicloalquiloxi C₃₋₈ o heterocicloalquiloxi de 3 a 12 miembros, en donde Rʸ se selecciona, de modo independiente, de alquilo C₁₋₇, cicloalquilo C₃₋₈, arilo C₆₋₁₀, heteroarilo de 5 a 10 miembros, heterocicloalquilo de 3 a 12 miembros, cicloalquilo C₃₋₈-alquilo C₁₋₇, aril C₆₋₁₀-alquilo C₁₋₇, heteroaril-alquilo C₁₋₇ de 5 a 10 miembros y heterocicloalquil-alquilo C₁₋₇ de 3 a 12 miembros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021130348 | 2021-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127653A1 true AR127653A1 (es) | 2024-02-14 |
Family
ID=86335121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103112A AR127653A1 (es) | 2021-11-12 | 2022-11-11 | Derivados de ésteres de n⁴-hidroxicitidina y su uso |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN116583530A (es) |
| AR (1) | AR127653A1 (es) |
| TW (1) | TW202342063A (es) |
| WO (1) | WO2023083295A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117886870A (zh) * | 2021-08-27 | 2024-04-16 | 南京知和医药科技有限公司 | 一种新型的胞苷衍生物及其药物组合物和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017013858A2 (pt) * | 2014-12-26 | 2018-02-27 | Univ Emory | n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos |
| CN111548384B (zh) * | 2020-03-29 | 2021-04-27 | 常州安蒂卫生物科技有限公司 | 用于抗病毒治疗的被取代的n4-羟基胞苷衍生物及其前药 |
-
2022
- 2022-11-11 WO PCT/CN2022/131334 patent/WO2023083295A1/en active Application Filing
- 2022-11-11 CN CN202280008132.1A patent/CN116583530A/zh active Pending
- 2022-11-11 AR ARP220103112A patent/AR127653A1/es unknown
- 2022-11-11 TW TW111143244A patent/TW202342063A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023083295A1 (en) | 2023-05-19 |
| CN116583530A (zh) | 2023-08-11 |
| TW202342063A (zh) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125414A2 (es) | INHIBIDORES DE INTEGRINA avb6 | |
| AR108812A1 (es) | Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo | |
| AR105648A1 (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos | |
| AR102722A2 (es) | Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR117617A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1 | |
| AR120680A1 (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| AR114235A1 (es) | Inhibidores de gcn2 y usos de los mismos | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR113909A1 (es) | Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| AR127653A1 (es) | Derivados de ésteres de n⁴-hidroxicitidina y su uso | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| AR115007A1 (es) | Derivados de triazolona o sales de los mismos y composiciones farmacéuticas que comprenden los mismos | |
| AR104880A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
| AR115006A1 (es) | Derivados de aril o heteroaril triazolona o sales de los mismos o composiciones farmacéuticas que comprenden los mismos | |
| AR121296A1 (es) | Moduladores de monoacilglicerol lipasa | |
| AR098723A1 (es) | Derivados de pirazolopirimidin-2-ilo como inhibidores de jak | |
| AR120773A1 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona como reductor de la actividad de la proteína wiz | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| PE20230182A1 (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter | |
| AR125213A2 (es) | Concentrado emulsionable que comprende un herbicida de ácido picolínico | |
| CL2023000387A1 (es) | Derivados de dioxoloisoquinolinona novedosos y uso de los mismos | |
| RU2019113149A (ru) | Низкомолекулярные активаторы амфк |